Minhu Chen
Sun Yat-sen University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Minhu Chen.
Inflammatory Bowel Diseases | 2012
Ren Mao; Yinglian Xiao; Xiang Gao; Bai-li Chen; Yao He; Li Yang; Pinjin Hu; Minhu Chen
Background: Fecal calprotectin (FC) is a relatively new marker of intestinal inflammation. Recently, many studies have extended its role in predicting relapse of quiescent inflammatory bowel disease (IBD), but the reported results have been inconsistent. We aimed to perform a meta‐analysis of the predictive capacity of FC in IBD relapse. Methods: We systematically searched the Medline, Web of Science, Cochrane Library, and EMBASE databases for prospective studies that used FC concentrations at remission in predicting relapse of Crohns disease (CD) and ulcerative colitis (UC). Pooled sensitivity, specificity, and other diagnostic indices were evaluated. Results: A total of 672 IBD patients (318 UC and 354 CD) from six different studies were analyzed. The pooled sensitivity and specificity of FC to predict relapse of quiescent IBD was 78% (95% confidence interval [CI]: 72–83) and 73% (95% CI: 68–77), respectively. The area under the summary receiver‐operating characteristic (sROC) curve was 0.83 and the diagnostic odds ratio was 10.31 (95% CI: 5.05–21.06). The capacity of FC to predict relapse was comparable between UC and CD. In CD patients the predictive value of FC in isolated small bowel CD was not assessed due to insufficiency of available data. Compared with all enrolled CD patients, FC appeared to be more accurate in ileocolonic and colonic CD. Conclusions: As a simple and noninvasive marker, FC is useful to predict relapse in quiescent IBD patients. (Inflamm Bowel Dis 2012)
BMC Gastroenterology | 2008
AnJiang Wang; XianHua Liao; Lishou Xiong; Sui Peng; Yinglian Xiao; SiChun Liu; PinJin Hu; Minhu Chen
BackgroundEpidemiological studies suggest considerable overlap between functional dyspepsia (FD) and irritable bowel syndrome (IBS). To date, no surveys have been performed to investigate the clinical overlap between these two disorders using Rome III criteria. Our aim was to investigate the prevalence and risk factors for the overlap of FD and IBS based on Rome III criteria in a large clinical sample.MethodsConsecutive patients at the general gastroenterology outpatient clinic were requested to complete a self-report questionnaire. FD and IBS were defined by Rome III criteria.ResultsQuestionnaires were returned by 3014 patients (52.8% female, 89% response rate). FD-IBS overlap was observed in 5.0% of the patients, while 15.2% and 10.9% of the patients were classified as FD alone and IBS alone, respectively. Compared with non-IBS patients, the odds ratio of having FD among IBS patients was 2.09 (95% CI: 1.68–2.59). Patients with FD-IBS overlap had higher severity scores for the postprandial fullness symptom (2.35 ± 1.49 vs. 1.72 ± 1.59, P < 0.001) and overall FD symptom (6.65 ± 2.88 vs. 5.82 ± 2.76, P = 0.002) than those with FD alone. The only independent risk factor for FD-IBS overlap vs. FD alone was the presence of postprandial fullness symptom (OR 2.67, 95% CI: 1.34–5.31).ConclusionClinical overlap of FD and IBS according to Rome III criteria is very common. One risk factor for FD-IBS overlap is the presence of postprandial fullness symptom. This study provides clues for future pathophysiological studies of FD and IBS.
Gut | 2015
Siew C. Ng; Whitney Tang; Rupert W. Leong; Minhu Chen; Yanna Ko; Corrie Studd; Ola Niewiadomski; Sally Bell; Michael A. Kamm; H.J. de Silva; A. Kasturiratne; Yasith Udara Senanayake; Choon Jin Ooi; Khoon-Lin Ling; David E. Ong; Khean-Lee Goh; Ida Hilmi; Qin Ouyang; Yu-Fang Wang; Pinjin Hu; Zhenhua Zhu; Zhirong Zeng; Kaichun Wu; Xin Wang; Bing Xia; Jin Li; Pises Pisespongsa; Sathaporn Manatsathit; Satimai Aniwan; Marcellus Simadibrata
Objective The rising incidence of inflammatory bowel disease in Asia supports the importance of environmental risk factors in disease aetiology. This prospective population-based case-control study in Asia-Pacific examined risk factors prior to patients developing IBD. Design 442 incident cases (186 Crohns disease (CD); 256 UC; 374 Asians) diagnosed between 2011 and 2013 from eight countries in Asia and Australia and 940 controls (frequency-matched by sex, age and geographical location; 789 Asians) completed an environmental factor questionnaire at diagnosis. Unconditional logistic regression models were used to estimate adjusted ORs (aOR) and 95% CIs. Results In multivariate model, being breast fed >12 months (aOR 0.10; 95% CI 0.04 to 0.30), antibiotic use (aOR 0.19; 0.07 to 0.52), having dogs (aOR 0.54; 0.35 to 0.83), daily tea consumption (aOR 0.62; 0.43 to 0.91) and daily physical activity (aOR 0.58; 0.35 to 0.96) decreased the odds for CD in Asians. In UC, being breast fed >12 months (aOR 0.16; 0.08 to 0.31), antibiotic use (aOR 0.48; 0.27 to 0.87), daily tea (aOR 0.63; 0.46 to 0.86) or coffee consumption (aOR 0.51; 0.36 to 0.72), presence of hot water tap (aOR 0.65; 0.46 to 0.91) and flush toilet in childhood (aOR 0.71; 0.51 to 0.98) were protective for UC development whereas ex-smoking (aOR 2.02; 1.22 to 3.35) increased the risk of UC. Conclusions This first population-based study of IBD risk factors in Asia-Pacific supports the importance of childhood immunological, hygiene and dietary factors in the development of IBD, suggesting that markers of altered intestinal microbiota may modulate risk of IBD later in life.
International Journal of Cancer | 2010
Xiaoqin Wu; Zhirong Zeng; Bin Chen; Jun Yu; Ling Xue; Yuantao Hao; Minhu Chen; Joseph J.Y. Sung; Pinjin Hu
Chronic inflammation is the hallmark of the pathogenesis of Helicobacter pylori‐induced gastric cancer. Interleukin (IL)‐17A and IL‐17F are inflammatory cytokines expressed by a novel subset of CD4+ Th cells and play critical function in inflammation and probably in cancer. We conducted a case–control study including 1,010 gastric cancer patients and 800 healthy controls to assess the association between IL‐17A G197A and IL‐17F A7488G polymorphisms and risk of gastric cancer. Genotypes were determined by polymerase chain reaction‐restriction fragment length polymorphism (PCR‐RFLP) and DNA sequencing. Logistic regression and Cox‐proportional hazards analyses were used to evaluate the associations between polymorphisms and gastric cancer susceptibility, clinicopathological features and survival. After adjusted for age and gender, IL‐17F 7488GA and GG genotypes were associated with an increased risk of gastric cancer compared with AA genotype [OR 1.51, 95% confidence interval (CI): 1.22–1.87 for GA; OR 1.61, 95% CI: 1.03–2.51 for GG]. Further stratification analyses indicated that the effect of IL‐17F 7488GA genotype was noteworthy in gastric cancer patients of noncardia, intestinal type, poorly and moderately differentiated, age older than 40, large tumor size and lymph node metastasis. IL‐17A 197AG genotype was associated with increased risk of poorly differentiated, TNM I/II, age of 40–65‐year subtypes of gastric cancer, but not with total gastric cancer risk (p = 0.098). No significant relationship was observed between polymorphisms and survival of gastric cancer patients. These findings suggest that polymorphism of IL‐17F 7488 involved in susceptibility to gastric cancer, which also influenced certain subtypes according to clinicopathological features, whereas IL‐17A 197 may be less relevant.
Scandinavian Journal of Gastroenterology | 2005
Minhu Chen; Lishou Xiong; Huixin Chen; Angao Xu; Longjun He; Pinjin Hu
Objective There are few data on the epidemiology of gastroesophageal reflux disease (GERD) in South China. The aim of this study was to assess the prevalence of GERD symptoms in South China and to evaluate the impact on health-related quality of life. Material and methods A face-to-face interview was carried out in South China using a validated Chinese version of the Reflux Disease Questionnaire to assess the prevalence of GERD symptoms. A randomly clustered sampling of permanent inhabitants aged 18 to 90 years was carried out under stratification of urban and suburban areas. The impact of GERD symptoms on health-related quality of life was evaluated using the Chinese version of SF-36. Results A total of 3338 residents (1468 M, 1870 F) were investigated. Mean age of the responders was 42.6±16.4 years; response rate was 95%. The prevalence of heartburn and/or acid eructation occurring at least weekly was 6.2%. The age- and gender-adjusted point prevalence of GERD symptoms in South China is 2.3% (95% CI, 1.8%, 2.8%) according to the definition in this study. There was no difference in prevalence between male (2.6%) and female (2.4%) subjects and there was no significant association between age and prevalence of GERD symptoms. Divorced/widowed/separated subjects (OR 4.61; 95% CI, 2.15%, 9.89%) and subjects with a heavy burden of work (OR 3.43, 95% CI, 1.72%, 6.84%) were significantly more likely to report GERD symptoms. As compared with the general population, subjects with GERD symptoms experienced considerable impairment in quality of life. Conclusions The prevalence of GERD symptoms in South China was much lower than that reported in Western countries. GERD had a negative impact on quality of life.
Journal of Gastroenterology and Hepatology | 2013
Zhirong Zeng; Zhenhua Zhu; Yuyu Yang; Weishan Ruan; Xiabiao Peng; Yuhuan Su; Lin Peng; Jinquan Chen; Quan Yin; Chao Zhao; Haihua Zhou; Shuai Yuan; Yuantao Hao; Jiaming Qian; Siew C. Ng; Minhu Chen; Pinjin Hu
The incidence of inflammatory bowel disease (IBD) is increasing in China with urbanization and socioeconomic development. There is however a lack of prospective, population‐based epidemiology study on IBD in China. The aim of the study is to define the incidence and clinical characteristics of IBD in a developed region of Guangdong Province in China.
The American Journal of Gastroenterology | 2010
Yinglian Xiao; Sui Peng; Jin Tao; An-Jiang Wang; Jin-Kun Lin; Pinjin Hu; Minhu Chen
OBJECTIVES:To determine the prevalence and symptom pattern of pathologic esophageal acid reflux (PEAR) in patients with functional dyspepsia (FD) using the Rome III criteria, and to explore the value of a proton pump inhibitor (PPI) test in distinguishing the patients with and those without PEAR among FD patients.METHODS:Consecutive FD patients who fulfilled the Rome III criteria without predominant typical reflux symptoms (i.e., heartburn or regurgitation) were enrolled. All patients underwent upper endoscopy and an ambulatory 24-h pH monitoring. PEAR was defined as the percentage total time for which a pH value <4 was >4.2% in the distal esophagus. Then, patients were treated with rabeprazole 10 mg twice daily for 28 days. The symptom scores were measured by the frequency score multiplied by the severity scores of the predominant symptom before and at the end of the treatment, and the “PPI test” was defined as positive if the overall scores of the predominant dyspeptic symptom in the fourth week decreased by >50% compared with those of the baseline.RESULTS:One hundred eighty-six FD patients were enrolled, with predominant symptoms of epigastric pain (n=68), epigastric burning (n=47), bothersome postprandial fullness (n=54), and early satiation (n=17). The prevalence of PEAR was 31.7%, with the highest percentage (48.9%) in patients with epigastric burning as their predominant symptom. The prevalence of PEAR in patients with postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS) were 36.6% (26/71) and 28.7% (33/115), respectively. Overall, 63.4% were positive for the “PPI test”; the rates were 51.5, 85.0, 66.7, and 41.1% in patients with epigastric pain, epigastric burning, bothersome postprandial fullness, and early satiation as their predominant symptoms, respectively (χ2=17.59, P=0.001). The positive rates were 65.5 and 60.6% in patients with PDS and EPS, respectively (χ2=0.41, P=0.522). The sensitivity and specificity of the “PPI test” in distinguishing FD patients with PEAR was 83.1 and 45.7%, respectively.CONCLUSIONS:PEAR is present in almost one third of FD patients; the prevalence is ∼50% in those with epigastric burning. The “PPI test” has a limited value in distinguishing the FD patients with and those without PEAR.
The American Journal of Gastroenterology | 2007
Zhao-Shen Li; Xue Pan; Wen-Jun Zhang; Biao Gong; Fa-Chao Zhi; Xue-Gang Guo; Pei-Ming Li; Zhi-Ning Fan; Wen-Sheng Sun; Yun-Zhi Shen; Shu-Ren Ma; Wei-Fen Xie; Minhu Chen; Yan-Qing Li
OBJECTIVES:Since the introduction of endoscopic retrograde cholangiopancreatology (ERCP) in clinical use, pancreatitis has become a common complication of ERCP. Octreotide is an inhibitor of pancreatic enzyme secretions. Several studies have evaluated the effect of octreotide on the incidence of clinical pancreatitis after ERCP, but with different results. The aim was to determine the efficacy of prophylactic administration of octreotide for the prevention of post-ERCP pancreatitis (PEP) and hyperamylasemia.METHODS:In this study, patients with scheduled ERCP were randomized to receive either octreotide (0.3 mg) via intramuscular injection or a placebo. The study was conducted in 12 digestive endoscopic units in China. Patients were randomized into two groups: an octreotide group (N = 414) and a control group (N = 418). In the octreotide group, octreotide (0.3 mg) was dissolved in 500 mL of 0.9% saline solution and administered by continuous intravenous infusion, beginning 1 h before endoscopic examination and continued for 6 h thereafter; 0.1 mg of octreotide was injected subcutaneously at 6 and 12 h after the intravenous injection was stopped. The control group was given a placebo intravenously. The end point was the development of acute pancreatitis.RESULTS:The overall incidence of acute pancreatitis was 3.85%; this included 2.42% (10/414) in the octreotide group and 5.26% (22/418) in the control group (P = 0.046). The overall incidence of hyperamylasemia was 14.9%; 12.32% (51/414) in the octreotide group and 17.46% (73/418) in the control group (P = 0.041). No side effects were found.CONCLUSION:The results indicate that octreotide can prevent PEP and hyperamylasemia.
The American Journal of Gastroenterology | 2014
Liya Zhou; Jianzhong Zhang; Minhu Chen; Xiaohua Hou; Zhao-Shen Li; Zhiqiang Song; Lihua He; Sanren Lin
OBJECTIVES:Studies conducted in large populations of patients and providing full information on Helicobacter pylori (H. pylori) antibiotic resistance are needed to determine the efficacy of sequential therapy (SQT) against this pathogen. This study compared eradication rates with SQT and standard triple therapy (STT), and evaluated the impact of antibiotic resistance on outcomes.METHODS:The study population included adults with positive H. pylori culture presenting at four centers in China between March 2008 and December 2010. Patients were randomly assigned to 10 days of treatment with esomeprazole, amoxicillin, and clarithromycin (STT; n=140) or to 5 days of treatment with esomeprazole and amoxicillin, followed by 5 days of esomeprazole, clarithromycin, and tinidazole (SQT; n=140). Eradication was assessed 8–12 weeks after treatment.RESULTS:There was no significant difference between the eradication rates achieved with STT (66.4% (95% confidence interval (CI) 59.3–74.3)) and SQT (72.1% (65.0–79.3); P=0.300) in either the intention-to-treat analysis or the per-protocol analysis (72.7% (65.6–79.7) and 76.5% (69.7–83.3), respectively; P=0.475). Clarithromycin resistance (CLA-R, odds ratio (OR)=8.34 (3.13–22.26), P<0.001) and metronidazole resistance (MET-R, OR=7.14 (1.52–33.53), P=0.013) both independently predicted treatment failure in the SQT group. Patients in the SQT group with dual CLA-R and MET-R had a lower eradication rate (43.9%) than those with isolated CLA-R (88.9%, P=0.024) or isolated MET-R (87.8%, P<0.001).CONCLUSIONS:H. pylori eradication rates with STT and SQT were compromised by antibiotic resistance. SQT may be suitable in regions with high prevalence of isolated CLA-R, but it is unsatisfactory when both CLA-R and MET-R are present.
International Journal of Cancer | 2013
Xiangbin Xing; Yong-Bo Tang; Gang Yuan; Yongfei Wang; JinHui Wang; Yang Yang; Minhu Chen
The prognostic impact of E‐cadherin downregulation in gastric cancer has been assessed for years while the results are controversial and heterogeneous. We thus comprehensively reviewed the evidence for evaluation of E‐cadherin expression in gastric cancer to determine this effect. We searched PubMed and Embase to identify eligible studies, and 26 studies comprising 4,383 gastric cancer patients were included to assess the association between E‐cadherin immunohistochemical expression and overall survival (OS) and clinicopathological characteristics. Summary hazard ratios (HRs) or odds ratios (ORs) with 95% confidence interval (95% CI) were calculated to estimate the effect. We also performed meta‐regression and subgroup analysis according to study location, publication year, number of patients, quality score of studies and cut‐off value. Reduced E‐cadherin expression was significantly correlated with poor OS of gastric cancer patients (HR 1.62, 95% CI 1.34–1.96). Subgroup analysis indicated that E‐cadherin low‐expression had an unfavorable impact on OS in Asian patients (HR 1.87, 95% CI 1.45–2.41). Moreover, downregulation of E‐cadherin was significantly associated with TNM stage (OR 2.52, 95% CI 1.85–3.43), the depth of invasion (OR 2.01, 95% CI 1.39–2.90), lymph node metastasis (OR 2.39, 95% CI 1.68–3.40), distant metastasis (OR 2.23, 95% CI 1.21–4.11), grade of differentiation (OR 2.26, 95% CI 1.60–3.21), vascular invasion (OR 1.86, 95% CI 1.10–3.13) and histological type of gastric cancer (OR 4.22, 95% CI 2.96–6.02). This meta‐analysis revealed that E‐cadherin expression might be a predicative factor of poor prognosis for gastric cancer particularly in Asia.